

Intra-articular Hyalubrix® injections versus local anaesthetic in hip osteoarthritis

Submission date 06/02/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 18/02/2009	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 30/12/2020	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Alberto Migliore

Contact details
Ospedale San Pietro FBF
Via Cassia, 600
Rome
Italy
00189
-
albertomigliore@terra.es

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
Q47-04-01

Study information

Scientific Title

Comparative, double blind, controlled study of intra-articular hyaluronic acid (Hyalubrix®) injections versus local anaesthetic in osteoarthritis of the hip

Study objectives

The study compared the benefit, duration and adverse event profile of intra-articular (IA) Hyalubrix® versus IA mepivacaine in the treatment of hip osteoarthritis (OA) using ultrasound-guidance to ensure IA injection.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Clinical Study Protocol (CSP) with all its appendices, including informed consent documentation, insurance and Summary of Product Characteristics were submitted for evaluation and approval to the competent Ethic Committee in the involved centre. The study received the favourable opinion by the Ethic Committee on the 9th November 2004.

Study design

Single-site prospective randomised double-blind controlled clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please contact Nicola Giordan at ngiordan@fidiapharma.it to request a patient information sheet

Health condition(s) or problem(s) studied

Hip osteoarthritis

Interventions

IA hip injections were guided by ultrasound using an anterosagittal in assistance of real-time ultrasound and Doppler imaging:

Active group: IA injection of Hyalubrix® 4 ml (2 syringes, 60 mg)

Control group: Mepivacaine 4 cc of 2%

Two treatment administrations: one at baseline, and the second one after one month.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Hyalubrix®, mepivacaine

Primary outcome measure

Determination of the change in the Lequesne index of the hip, comparing IA Hyalubrix® to IA mepivacaine at 26 weeks.

Secondary outcome measures

Measured 90 and 180 days after first injection:

1. Pain intensity (recorded on a 10 cm VAS)
2. Patient record of non-steroidal anti-inflammatory drug (NSAID) consumption
3. Patients global assessment
4. Examining physician's global assessment
5. Demographic correlations to response
6. Hyaluronic acid (HA) safety

Overall study start date

09/11/2004

Completion date

30/06/2007

Eligibility**Key inclusion criteria**

1. Aged greater than 40 years, either sex
2. Ambulant without assistance
3. Hip OA by American College of Rheumatology (ACR) radiographic criteria
4. Baseline Visual Analogue Scale (VAS) score of greater than 4 cm
5. Persistence of hip pain for at least 1 month before baseline
6. Signed informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

40 participants (20 patients for arm)

Total final enrolment

42

Key exclusion criteria

1. Comorbidities (e.g. rheumatoid arthritis, avascular necrosis, fibromyalgia)
2. Infection around the injection site
3. Treatment with oral, parenteral, or IA steroids within 3 months
4. Use of anticoagulants or history of thrombocytopaenia
5. Allergy to local anaesthetics
6. History of adverse reaction to IA Hyalubrix®
7. Pending hip replacement surgery
8. Use of a purported OA disease modifying agent

Date of first enrolment

09/11/2004

Date of final enrolment

30/06/2007

Locations**Countries of recruitment**

Italy

Study participating centre

Ospedale San Pietro FBF

Rome

Italy

00189

Sponsor information**Organisation**

Fidia Farmaceutici S.p.A. (Italy)

Sponsor details

Via ponte della fabbrica 3/A

Abano Terme

Padova

Italy

35031

-

ngiordan@fidiapharma.it

Sponsor type

Industry

Website

<http://www.fidiapharma.it>

ROR

<https://ror.org/00dy5wm60>

Funder(s)

Funder type

Industry

Funder Name

Fidia Farmaceutici S.p.A. (Italy)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2009	30/12/2020	Yes	No